Global chemicals mergers and acquisitions have staged a decisive rebound, with deal value reaching $67 billion on a trailing twelve-month basis in the first quarter of 2026 across 552 transactions, according to industry trackers. The recovery, up 18% over 2025 and surpassing the seven-year average, was driven overwhelmingly by four mega-transactions, Borealis-Borouge, AkzoNobel-Axalta, OMV and ADNOC’s acquisition of Nova Chemicals, and Berkshire Hathaway’s purchase of OxyChem, which together accounted for roughly 40% of total deal activity in the period.
The concentration of value in a handful of landmark transactions signals a market that remains selective and defensive rather than broadly exuberant. Dealmakers are pricing in structural shifts across the industry rather than betting on a cyclical upswing in commodity chemical demand. Basic chemicals assets are currently trading at an EV/EBITDA multiple of 8.57 times and EV/Sales of 0.85 times, reflecting continued caution toward commodity-exposed businesses, while specialty chemicals command a substantially richer 13.36 times EV/EBITDA and 2.65 times EV/Sales, underscoring the premium investors are willing to pay for differentiated, less cyclical assets.
Roughly two-thirds of all chemical deals over the past eighteen months have targeted specialty chemicals, proprietary technology platforms, and sustainability-linked businesses, according to Kearney’s latest M&A analysis. This marks a pronounced strategic pivot away from commodity assets, which continue to face structural valuation pressure, particularly in Europe, where high energy costs, regulatory complexity, soft downstream demand and a wave of Chinese capacity additions are compressing margins and depressing multiples for undifferentiated producers.
The scarcity value embedded in quality specialty assets is increasingly evident in deal pricing. Transactions for businesses with genuine technology differentiation or carve-out potential, where a divestiture creates a clear operational turnaround runway for the buyer, are pricing above public market trading levels. This dynamic reflects strategic buyers and private equity sponsors competing for a shrinking pool of high-quality specialty targets, even as the broader commodity chemicals landscape remains largely out of favour with dealmakers.
Wood Mackenzie and other industry advisers note that the M&A rebound is unfolding against a backdrop of fading macro uncertainty, with easing trade tensions and more stable input costs giving boards greater confidence to pursue transformational transactions. Still, the sector faces persistent headwinds: chemical company executives cite tariff exposure, trade fragmentation and global overcapacity as key risks weighing on 2026 planning, particularly for companies with significant exposure to China’s expanding petrochemical base.
Looking forward, deal advisers expect the specialty-chemicals-led M&A pattern to persist through the remainder of 2026, with commodity assets requiring far more compelling strategic rationale, such as feedstock integration or geographic diversification, to attract buyer interest at reasonable valuations. For an industry navigating a genuine inflection point between volume-driven growth and value-led leadership, the current wave of mega-deals suggests that capital is flowing decisively toward businesses that can demonstrate pricing power, technological differentiation and resilience to commodity cycles, a trend likely to define the competitive landscape for years to come.
For India-linked strategic buyers and global majors eyeing the country’s fast-growing chemicals market, the M&A rebound carries direct relevance. India’s specialty and construction-linked chemicals segments are among the fastest-expanding in the world, and global consolidation trends in high-margin, technology-driven categories are likely to spur cross-border interest in Indian specialty producers as multinational players seek exposure to the country’s domestic demand growth alongside its increasingly competitive export base.
Leave a comment